Analyst Arthur He CFA from H.C. Wainwright maintained a Buy rating on Vera Therapeutics and keeping the price target at $110.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Arthur He CFA has given his Buy rating due to a combination of factors, including the advanced regulatory status and differentiated profile of atacicept in IgA nephropathy. He highlights that the biologics license application is progressing toward a July 7, 2026 PDUFA date, and he views approval as highly probable given robust ORIGIN 2 and ORIGIN 3 results and the established regulatory pathway for IgAN therapies.
He also points to additional value from the PIONEER basket study, which may extend atacicept’s use into broader IgAN populations and other autoimmune kidney diseases, reinforcing a pipeline-in-a-product thesis. In his view, Vera’s strong cash position should fund operations through potential approval and launch, while a risk-adjusted NPV analysis of atacicept’s future revenues supports an unchanged $110 price target despite clinical, regulatory, commercial, competitive, and dilution risks.
According to TipRanks, He CFA is a 5-star analyst with an average return of 41.1% and a 59.57% success rate. He CFA covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Jade Biosciences, and Solid Biosciences.
In another report released on May 10, Guggenheim also reiterated a Buy rating on the stock with a $56.00 price target.